Tumor vascular heterogeneity and the impact of subtumoral nanoemulsion biodistribution

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. De Vita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 68(21), 8643–8653 (2008).
  MedlineGoogle Scholar
• 2. Camara ALD, Nagel G, Tschiche HR et al. Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs lung tumor metastasis in a breast cancer model. Nanomedicine 12(15), 1751–1765 (2017). • This article was the first report from the authors' group that described the biodistribution of a lipid nanoemulsion.
  CASGoogle Scholar
• 3. de Lima LI, Faria RS, Franco MS et al. Combined paclitaxel-doxorubicin liposomal results in positive prognosis with infiltrating lymphocytes in lung metastasis. Nanomedicine 15(29), 2753–2770 (2020).
  CASGoogle Scholar
• 4. Tunggal JK, Cowan DS, Shaikh H, Tannock IF. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin. Cancer Res. 5(6), 1583–1586 (1999).
  Medline CASGoogle Scholar
• 5. Munn LL. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov. Today 8(9), 396–403 (2003).
  MedlineGoogle Scholar
• 6. Chauhan VP, Stylianopoulos T, Martin JD et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7(6), 383–388 (2012).
  Medline CASGoogle Scholar
• 7. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46(12 Pt 1), 6387–6392 (1986).
  Medline CASGoogle Scholar
• 8. Longo J, Muehlmann L, Almeida-Santos M, Azevedo R. Preventing metastasis by targeting lymphatic vessels with photodynamic therapy based on nanostructured photosensitizers. J. Nanomed. Nanotechnol. 6(5), 1 (2015).
  Google Scholar
• 9. Ngoune R, Peters A, von Elverfeldt D, Winkler K, Pütz G. Accumulating nanoparticles by EPR: a route of no return. J. Control. Rel. 238, 58–70 (2016). •• This article presents several important concepts used in the literature involving the enhanced permeability and retention effect.
  Medline CASGoogle Scholar
• 10. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63(3), 131–135 (2011). • This article presents several important concepts used in the literature involving the delivery of nanoparticles to tumor tissues.
  Medline CASGoogle Scholar
• 11. Nakamura Y, Mochida A, Choyke PL, Kobayashi H. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug. Chem. 27(10), 2225–2238 (2016).
  Medline CASGoogle Scholar
• 12. Arami H, Patel CB, Madsen SJ et al. Nanomedicine for spontaneous brain tumors: a companion clinical trial. ACS Nano 13(3), 2858–2869 (2019).
  Medline CASGoogle Scholar
• 13. Ganassin R, Horst FH, Camargo NS et al. Selol nanocapsules with a poly(methyl vinyl ether-co-maleic anhydride) shell conjugated to doxorubicin for combinatorial chemotherapy against murine breast adenocarcinoma in vivo. Artif. Cells Nanomed. Biotechnol. 46(2), 1046–1052 (2018).
  Medline CASGoogle Scholar
• 14. Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv. Drug Deliv. Rev. 63(3), 184–192 (2011).
  Medline CASGoogle Scholar
• 15. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9(1), 1–14 (2013).
  Medline CASGoogle Scholar
• 16. Longo JPF, Lucci CM, Muehlmann LA, Azevedo RB. Nanomedicine for cutaneous tumors – lessons since the successful treatment of the Kaposi sarcoma. Nanomedicine 13(23), 2957–2959 (2018). •• This article describes a brief discussion about the use of drug nanocarriers for oncology applications.
  Google Scholar
• 17. Figueiró Longo JP, Muehlmann LA. Nanomedicine beyond tumor passive targeting: what next? Nanomedicine 15(19), 1819–1822 (2020). •• This article presents a short discussion about the use of nanoparticles for different medical conditions.
  Google Scholar
• 18. Wilhelm S, Tavares AJ, Dai Q et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016). •• This article presents an important meta-analysis discussing the passive delivery of drug nanocarriers for tumor tissues.
  CASGoogle Scholar
• 19. Sindhwani S, Syed AM, Ngai J et al. The entry of nanoparticles into solid tumours. Nat. Mater. 19, 566–575 (2020).
  Medline CASGoogle Scholar
• 20. Jiang W, Huang Y, An Y, Kim BY. Remodeling tumor vasculature to enhance delivery of intermediate-sized nanoparticles. ACS Nano 9(9), 8689–8696 (2015).
  Medline CASGoogle Scholar
• 21. Ganassin R, Souza LR, Py-Daniel KR et al. Decoration of a poly(methyl vinyl ether-co-maleic anhydride)-shelled selol nanocapsule with folic acid increases its activity against different cancer cell lines. J. Nanosci. Nanotechnol. 18(1), 522–528 (2018).
  Medline CASGoogle Scholar
• 22. Radicchi MA, de Oliveira JV, Mendes ACP et al. Lipid nanoemulsion passive tumor accumulation dependence on tumor stage and anatomical location: a new mathematical model for in vivo imaging biodistribution study. J. Mater. Chem. B 6(44), 7306–7316 (2018). •• This article describes the differential biodistribution of lipid nanoparticles depending upon the tumor maturation. Young tumors will capture nanoemulsions in a different way than mature, more developed tumors.
  Medline CASGoogle Scholar
• 23. Lee T-R, Choi M, Kopacz AM, Yun S-H, Liu WK, Decuzzi P. On the near-wall accumulation of injectable particles in the microcirculation: smaller is not better. Sci. Rep. 3(1), 1–8 (2013).
  Google Scholar
• 24. Sweeney LM, MacCalman L, Haber LT, Kuempel ED, Tran CL. Bayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in rats. Regul. Toxicol. Pharmacol. 73(1), 151–163 (2015).
  Medline CASGoogle Scholar
• 25. Tsoi KM, MacParland SA, Ma X-Z et al. Mechanism of hard-nanomaterial clearance by the liver. Nat. Mater. 15(11), 1212–1221 (2016).
  Medline CASGoogle Scholar
• 26. Miranda-Vilela AL, Peixoto RCA, Longo JPF et al. Dextran-functionalized magnetic fluid mediating magnetohyperthermia combined with preventive antioxidant pequi-oil supplementation: potential use against cancer. J. Biomed. Nanotechnol. 9(7), 1261–1271 (2013).
  Medline CASGoogle Scholar
• 27. Muehlmann LA, Rodrigues MC, Longo JPF et al. Aluminium-phthalocyanine chloride nanoemulsions for anticancer photodynamic therapy: development and in vitro activity against monolayers and spheroids of human mammary adenocarcinoma MCF-7 cells. J. Nanobiotechnol. 13, 13–36 (2015).
  Google Scholar
• 28. Campbell RB, Fukumura D, Brown EB et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 62(23), 6831–6836 (2002).
  Medline CASGoogle Scholar
• 29. Brochot C, Bessoud B, Balvay D, Cuénod C-A, Siauve N, Bois FY. Evaluation of antiangiogenic treatment effects on tumors' microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging. Magn. Reson. Imaging 24(8), 1059–1067 (2006).
  Medline CASGoogle Scholar
• 30. dos Santos MSC, Gouvêa AL, de Moura LD et al. Nanographene oxide-methylene blue as phototherapies platform for breast tumor ablation and metastasis prevention in a syngeneic orthotopic murine model. J. Nanobiotechnol. 16(1), 1–17 (2018).
  MedlineGoogle Scholar
• 31. Björnmalm M, Thurecht KJ, Michael M, Scott AM, Caruso F. Bridging bio-nano science and cancer nanomedicine. ACS Nano 11(10), 9594–9613 (2017).
  Medline CASGoogle Scholar
• 32. Bertrand N, Leroux J-C. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J. Control. Rel. 161(2), 152–163 (2012).
  Medline CASGoogle Scholar
• 33. Longo JPF, MuehInnann LA, Miranda-Vilela AL et al. Prevention of distant lung metastasis after photodynamic therapy application in a breast cancer tumor model. J. Biomed. Nanotechnol. 12(4), 689–699 (2016).
  Medline CASGoogle Scholar
• 34. Portilho FA, Cavalcanti CED, Miranda-Vilela AL et al. Antitumor activity of photodynamic therapy performed with nanospheres containing zinc-phthalocyanine. J. Nanobiotechnol. 11(41), 1–14 (2013).
  MedlineGoogle Scholar
• 35. Longo JPF, de Melo LND, Mijan MC et al. Photodynamic therapy mediated by liposomal chloroaluminum-phthalocyanine induces necrosis in oral cancer cells. J. Biomater. Tissue Eng. 3(1), 148–156 (2013).
  CASGoogle Scholar
• 36. Bicalho LS, Longo JP, Cavalcantil CEO et al. Photodynamic therapy leads to complete remission of tongue tumors and inhibits metastases to regional lymph nodes. J. Biomed. Nanotechnol. 9(5), 811–818 (2013).
  Medline CASGoogle Scholar
• 37. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7(11), 653–664 (2010). •• This article presents several important concepts used in the literature involving the delivery of nanoparticles to tumor tissues.
  Medline CASGoogle Scholar
• 38. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 64, S353–S365 (2012).
  MedlineGoogle Scholar
• 39. Longo JPF, Lozzi SP, Simioni AR, Morais PC, Tedesco AC, Azevedo RB. Photodynamic therapy with aluminum-chloro-phtalocyanine induces necrosis and vascular damage in mice tongue tumors. J. Photochem. Photobiol. B 94(2), 143–146 (2009).
  Medline CASGoogle Scholar
• 40. Almeida JPM, Chen AL, Foster A, Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine 6(5), 815–835 (2011).
  CASGoogle Scholar
• 41. Poisson J, Lemoinne S, Boulanger C et al. Liver sinusoidal endothelial cells: physiology and role in liver diseases. J. Hepatol. 66(1), 212–227 (2017).
  Medline CASGoogle Scholar
• 42. Kim J-W, Gao P, Dang CV. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev. 26(2), 291–298 (2007).
  MedlineGoogle Scholar
• 43. Sousa-Junior AA, Mendanha SA, Carriao MS et al. Predictive model for delivery efficiency: erythrocyte membrane-camouflaged magneto-fluorescent nanocarriers study. Mol. Pharm. 17(3), 837–851 (2020).
  Medline CASGoogle Scholar
• 44. Lazarovits J, Sindhwani S, Tavares AJ et al. Supervised learning and mass spectrometry predicts the in vivo fate of nanomaterials. ACS Nano 13(7), 8023–8034 (2019).
  Medline CASGoogle Scholar
• 45. Adir O, Poley M, Chen G et al. Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv. Mater. 32(13), e1901989 (2019).
  MedlineGoogle Scholar
• 46. Lacava LM, Lacava ZG, Da Silva MF et al. Magnetic resonance of a dextran-coated magnetic fluid intravenously administered in mice. Biophys. J. 80(5), 2483–2486 (2001).
  Medline CASGoogle Scholar
• 47. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin. Pharmacokinet. 42(5), 419–436 (2003).
  Medline CASGoogle Scholar
• 48. Potter DM. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer. Stat. Med. 21(13), 1805–1823 (2002).
  MedlineGoogle Scholar
• 49. Pagani O, Sessa C, Nole F et al. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann. Oncol. 11(8), 985–991 (2000).
  Medline CASGoogle Scholar
• 50. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metabol. 18(2), 153–161 (2013).
  Medline CASGoogle Scholar
• 51. Luo X, Zhao X, Cheng C, Li N, Liu Y, Cao Y. The implications of signaling lipids in cancer metastasis. Exp. Mol. Med. 50(9), 1–10 (2018).
  Google Scholar
• 52. Zheng J, Yu M, Hsieh J-T, Kapur P. Correlating anticancer drug delivery with vascular permeability of nanocarriers: renal clearable vs. non-renal clearable ones. Angew. Chem. 58(35), 12076–12080 (2020).
  Google Scholar
• 53. Sicklick JK, Kato S, Okamura R et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25(5), 744–750 (2019).
  Medline CASGoogle Scholar